Trial Profile
Impact of Irbesartan on Oxidative Stress and C-Reactive Protein Levels in Patients With Persistent Atrial Fibrillation.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Irbesartan (Primary)
- Indications Atrial fibrillation
- Focus Pharmacodynamics
- Acronyms CREATIVE-AF
- 23 Jun 2012 Status changed from recruiting to discontinued as reported by European Clinical Trials Database.
- 23 Jun 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2007-003262-17).
- 05 Jun 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.